Abstract
BackgroundIt has been recommended by the American Society of Clinical Oncology and the American Society of Reproductive Medicine that options to preserve fertility be presented at the outset of treatment for cancer. This recommendation may have arisen, in part, to the increasing survival of patients with cancer and the realization that certain forms of cancer treatment can lead to infertility. One option for these patients, particularly those with ethical or religious objections to freezing embryos is oocyte cryopreservation. However universal acceptance of these procedures has yet to be established, most likely due to a poor history of success and concerns that there has yet to be a comprehensive approach to evaluating these techniques. In light of this, a registry of patients undergoing oocyte cryopreservation, called the HOPE registry, is being implemented.DiscussionThe intent of the HOPE Registry is to enroll approximately 400 women of reproductive age who will undergo thawing/warming of oocytes and subsequent transfer. Data from the patients enrolled will be collected via a uniform, standardized form and will document important parameters such as demographics, laboratory procedures and outcomes, including following the outcomes of babies born for one year after birth. The results of the registry will be published on a yearly basis.SummaryA patient registry has been established in order to systematically document the techniques and outcomes of oocyte cryopreservation procedures. The results will be published in order to provide a widely accessible resource that will allow patients who are considering these procedures validated information in order to make informed decisions as to how their treatment will proceed.
Highlights
It has been recommended by the American Society of Clinical Oncology and the American Society of Reproductive Medicine that options to preserve fertility be presented at the outset of treatment for cancer
Goodwin et al estimated that 53 to 89% of breast cancer patients treated with chemotherapy undergo premature menopause, and that the risk for premature menopause was found to be strongly associated with the age of the patient and the use of systemic chemotherapy [4]
These concerns have been elucidated by recent guidelines and reports issued by ASRM's Committees report on this topic, which contend that, to date, the number of patients treated with oocyte cryopreservation, is inadequate to determine if the procedure has an effect on the development of children [25], and that because data is limited, the procedure should not be marketed as a method to defer reproductive aging [26]
Summary
The HOPE Registry will be the first prospective US registry to validate the efficacy and safety of oocyte cryopreservation techniques being utilized under IRB approval. Through the HOPE Registry, a real-world view of oocyte cryopreservation will be obtained, and with it, answers to many unresolved questions from healthcare providers and their patients who utilize this technique to preserve fertility for a variety of reasons. Oocyte cryopreservation may become a tool for successfully preserving female gametes, facilitating the formation of oocyte cryobanks that transform the paradigm of oocyte donation, thereby bringing hope to women who would otherwise have no option for childbearing
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
